6:18 PM
 | 
Jun 09, 2011
 |  BC Extra  |  Company News

FDA issues warning on BPH drugs

FDA said it updated the labels for 5-alpha reductase inhibitors to include information about an increased risk of high-grade prostate cancer. The agency said the risk "appears to be low." The change followed FDA's review of data...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >